A morphometric analysis of hepatitis B subviral particles shows no correlation of filament proportion and length with clinical stage and genotype.
electron microscopy
genotype
hepatitis B virus
liver disease stage
morphometric analysis
subviral particle
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
11
04
2022
received:
26
01
2022
accepted:
04
05
2022
pubmed:
29
5
2022
medline:
12
8
2022
entrez:
28
5
2022
Statut:
ppublish
Résumé
It was recently suggested that the composition of circulating hepatitis B subviral particles (SVPs) could be used to differentiate the various stages in chronic hepatitis B virus (HBV) infection, with significantly lower proportions of L and M proteins in inactive carriers than in individuals with chronic hepatitis. L protein is abundant in virions and filamentous SVPs but almost absent from spherical SVPs. We, therefore, performed a morphometric analysis of SVPs in these two groups of patients, by conducting a retrospective analysis on sera from 15 inactive carriers and 11 patients with chronic hepatitis infected with various HBV genotypes. Subviral particles were concentrated by centrifugation on a sucrose cushion, with monitoring by transmission electron microscopy. The percentage of filamentous SVPs and filament length for 100 SVPs was determined with a digital camera. The L protein PreS1 promoter was sequenced from viral genomes by the Sanger method. No marked differences were found between patients, some of whom had only spherical SVPs, whereas others had variable percentages of filamentous SVPs (up to 28%), of highly variable length. High filament percentages were not associated with a particular sequence of the L protein promoter, HBV genotype or even disease stage. High levels of circulating filamentous SVPs are probably more strongly related to individual host factors than to viral strain characteristics or disease stage.
Identifiants
pubmed: 35633087
doi: 10.1111/jvh.13712
pmc: PMC9541738
doi:
Substances chimiques
Hepatitis B Surface Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
719-726Informations de copyright
© 2022 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd.
Références
J Hepatol. 2002 Apr;36(4):543-6
pubmed: 11943427
Liver Int. 2020 Feb;40(2):324-332
pubmed: 31721419
Genes (Basel). 2018 Sep 27;9(10):
pubmed: 30262738
Intervirology. 2014;57(3-4):232-6
pubmed: 25034493
Proc Natl Acad Sci U S A. 1987 Oct;84(19):6909-13
pubmed: 3477814
Aliment Pharmacol Ther. 2018 Jun;47(11):1523-1535
pubmed: 29637585
J Viral Hepat. 2021 Sep;28(9):1304-1311
pubmed: 34105859
J Hepatol. 2003 Dec;39(6):1085-9
pubmed: 14642631
J Virol. 2015 Dec 30;90(7):3330-41
pubmed: 26719264
J Virol. 1984 Nov;52(2):396-402
pubmed: 6492255
Cell Microbiol. 2009 Nov;11(11):1561-70
pubmed: 19673892
J Hepatol. 2021 Feb;74(2):283-292
pubmed: 32931877
Gut. 2018 Nov;67(11):2045-2053
pubmed: 28951526
J Viral Hepat. 2018 Nov;25(11):1226-1235
pubmed: 30187603
Clin Infect Dis. 2006 Jun 1;42(11):1608-18
pubmed: 16652319
J Viral Hepat. 2022 Sep;29(9):719-726
pubmed: 35633087
Viruses. 2020 Jan 30;12(2):
pubmed: 32019103
J Hepatol. 2008 Dec;49(6):884-91
pubmed: 18674840
Gastroenterology. 1992 Mar;102(3):956-62
pubmed: 1537531
J Hepatol. 2017 Feb;66(2):398-411
pubmed: 27575311
J Infect Dis. 2018 Jun 5;218(1):114-123
pubmed: 29528436